PMID- 33241036
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220830
IS  - 2305-5839 (Print)
IS  - 2305-5847 (Electronic)
IS  - 2305-5839 (Linking)
VI  - 8
IP  - 18
DP  - 2020 Sep
TI  - Effectiveness and safety of toripalimab, camrelizumab, and sintilimab in a 
      real-world cohort of hepatitis B virus associated hepatocellular carcinoma 
      patients.
PG  - 1187
LID - 10.21037/atm-20-6063 [doi]
LID - 1187
AB  - BACKGROUND: The clinical significance of programmed cell death protein-1 
      (PD-1)-targeted immunotherapy in Chinese patients is understudied. We thus aimed 
      to evaluate the safety and efficacy of PD-1 inhibitors with toripalimab, 
      camrelizumab or sintilimab for Chinese hepatocellular carcinoma (HCC) patients in 
      a real-life cohort. METHODS: We analysed hepatitis B virus (HBV)-associated HCC 
      patients treated with toripalimab, camrelizumab, or sintilimab in a retrospective 
      single-center cohort from November 2018 to June 2020. Efficacy was evaluated with 
      objective response rate (ORR), disease control rate (DCR), progression-free 
      survival (PFS), time to tumor progression (TTP), and overall survival (OS). 
      Safety data were also recorded. RESULTS: Seventy patients were finally included 
      in the analysis: 23 were treated with toripalimab, 33 with camrelizumab, and 14 
      with sintilimab. The mean duration of follow-up was 44.7 (95% CI: 39.9-49.6) 
      weeks and the mean cycles of PD-1 at cutoff were 8.3+/-8.0 for all patients. The 
      ORR and DCR for the whole cohort were 30% and 72.9%, respectively. Overall, 25 
      (35.7%) patients had radiological disease progression and 10 (14.3%) patients 
      died during follow-up. Median PFS, median TTP, and median OS had not yet been 
      reached. Most frequent drug-related adverse events (AEs) were rash (27.1%), 
      hypertension (18.6%), fatigue (17.1%), diarrhea (17.1%), paresthesia (15.7%), and 
      nausea (15.7%). CONCLUSIONS: Our findings suggest that (I) PD-1 targeted 
      immunotherapy with toripalimab, camrelizumab, or sintilimab yielded a promising 
      outcome in Chinese HBV patients with HCC and that (II) immunotherapy was well 
      tolerated generally and had manageable side effects. This approach thus warrants 
      further popularization and application in clinical practice.
CI  - 2020 Annals of Translational Medicine. All rights reserved.
FAU - Chen, Jinzhang
AU  - Chen J
AD  - Department of Infectious Diseases and Hepatology Unitl, Southern Medical 
      University, Guangzhou, China.
AD  - Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, 
      China.
FAU - Hu, Xiaoyun
AU  - Hu X
AD  - Department of Infectious Diseases and Hepatology Unitl, Southern Medical 
      University, Guangzhou, China.
FAU - Li, Qi
AU  - Li Q
AD  - Department of Infectious Diseases and Hepatology Unitl, Southern Medical 
      University, Guangzhou, China.
AD  - Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, 
      China.
FAU - Dai, Wencong
AU  - Dai W
AD  - Department of Infectious Diseases and Hepatology Unitl, Southern Medical 
      University, Guangzhou, China.
FAU - Cheng, Xiao
AU  - Cheng X
AD  - Department of Infectious Diseases and Hepatology Unitl, Southern Medical 
      University, Guangzhou, China.
FAU - Huang, Wei
AU  - Huang W
AD  - Department of Oncology, ShunDe Hospital, Southern Medical University, Guangzhou, 
      China.
FAU - Yu, Wenxuan
AU  - Yu W
AD  - Department of Infectious Diseases and Hepatology Unitl, Southern Medical 
      University, Guangzhou, China.
FAU - Chen, Mian
AU  - Chen M
AD  - Transplant Immunology Laboratory, Churchill Hospital, Oxford University Hospitals 
      NHS Foundation Trust, Old Road, Headington, Oxford, UK.
FAU - Guo, Yabing
AU  - Guo Y
AD  - Department of Infectious Diseases and Hepatology Unitl, Southern Medical 
      University, Guangzhou, China.
FAU - Yuan, Guosheng
AU  - Yuan G
AD  - Department of Infectious Diseases and Hepatology Unitl, Southern Medical 
      University, Guangzhou, China.
LA  - eng
PT  - Journal Article
PL  - China
TA  - Ann Transl Med
JT  - Annals of translational medicine
JID - 101617978
PMC - PMC7576044
OTO - NOTNLM
OT  - Hepatocellular carcinoma (HCC)
OT  - anti-programmed cell death protein-1 antibody (anti-PD-1 antibody)
OT  - camrelizumab
OT  - programmed death receptor-1
OT  - sintilimab
OT  - toripalimab
COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure 
      form (available at http://dx.doi.org/10.21037/atm-20-6063). The authors have no 
      conflicts of interest to declare.
EDAT- 2020/11/27 06:00
MHDA- 2020/11/27 06:01
PMCR- 2020/09/01
CRDT- 2020/11/26 05:48
PHST- 2020/11/26 05:48 [entrez]
PHST- 2020/11/27 06:00 [pubmed]
PHST- 2020/11/27 06:01 [medline]
PHST- 2020/09/01 00:00 [pmc-release]
AID - atm-08-18-1187 [pii]
AID - 10.21037/atm-20-6063 [doi]
PST - ppublish
SO  - Ann Transl Med. 2020 Sep;8(18):1187. doi: 10.21037/atm-20-6063.